1
|
Gleeson LL, Clyne B, Barlow JW, Ryan B, Murphy P, Wallace E, De Brún A, Mellon L, Hanratty M, Ennis M, Holton A, Pate M, Kirke C, Flood M, Moriarty F. Medication safety incidents associated with the remote delivery of primary care: a rapid review. Int J Pharm Pract 2022; 30:495-506. [PMID: 36595375 DOI: 10.1093/ijpp/riac087] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 10/18/2022] [Indexed: 01/04/2023]
Abstract
OBJECTIVES The COVID-19 pandemic triggered rapid, fundamental changes, notably increased remote delivery of primary care. While the impact of these changes on medication safety is not yet fully understood, research conducted before the pandemic may provide evidence for possible consequences. To examine the published literature on medication safety incidents associated with the remote delivery of primary care, with a focus on telemedicine and electronic prescribing. METHODS A rapid review was conducted according to the Cochrane Rapid Reviews Methods Group guidance. An electronic search was carried out on Embase and Medline (via PubMed) using key search terms 'medication error', 'electronic prescribing', 'telemedicine' and 'primary care'. Identified studies were synthesised narratively; reported medication safety incidents were categorised according to the WHO Conceptual Framework for the International Classification for Patient Safety. KEY FINDINGS Fifteen studies were deemed eligible for inclusion. All 15 studies reported medication incidents associated with electronic prescribing; no studies were identified that reported medication safety incidents associated with telemedicine. The most commonly reported medication safety incidents were 'wrong label/instruction' and 'wrong dose/strength/frequency'. The frequency of medication safety incidents ranged from 0.89 to 81.98 incidents per 100 electronic prescriptions analysed. SUMMARY This review of medication safety incidents associated with the remote delivery of primary care identified common incident types associated with electronic prescriptions. There was a wide variation in reported frequencies of medication safety incidents associated with electronic prescriptions. Further research is required to determine the impact of the COVID-19 pandemic on medication safety in primary care, particularly the increased use of telemedicine.
Collapse
Affiliation(s)
- Laura L Gleeson
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Barbara Clyne
- Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - James W Barlow
- Department of Chemistry, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Benedict Ryan
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | | | - Emma Wallace
- Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Aoife De Brún
- UCD Centre for Interdisciplinary Research, Education and Innovation in Health Systems (UCD IRIS), School of Nursing, Midwifery & Health Systems, University College Dublin, Ireland
| | - Lisa Mellon
- Division of Population Health Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Marcus Hanratty
- Department of Product Design, National College of Art and Design, Dublin, Ireland
| | - Mark Ennis
- TU Dublin School of Creative Arts, Technological University Dublin City Campus, Dublin, Ireland
| | - Alice Holton
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Muriel Pate
- Quality and Safety Directorate, Health Service Executive, Ireland
| | - Ciara Kirke
- Quality and Safety Directorate, Health Service Executive, Ireland
| | - Michelle Flood
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Frank Moriarty
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| |
Collapse
|
2
|
Evans B, Ellsmere J, Hossain I, Ennis M, O'Brien E, Bacque L, Ge M, Brodie J, Harnett J, Borgaonkar M, Pace D. Colonoscopy skills improvement training improves patient comfort during colonoscopy. Surg Endosc 2022; 36:4588-4592. [PMID: 34622297 DOI: 10.1007/s00464-021-08753-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Accepted: 09/27/2021] [Indexed: 01/29/2023]
Abstract
INTRODUCTION We aimed to assess the effect of Colonoscopy Skills Improvement (CSI) training on patient comfort and sedation-related complications during colonoscopy. METHODS This retrospective cohort study was performed on 19 endoscopists practicing in a Canadian tertiary care center who completed CSI training between October 2014 and May 2016. Data from 50 procedures immediately prior to, immediately after, and eight months following CSI training were included for each endoscopist. The primary outcome variable was intraprocedural comfort, and secondary outcomes included intraprocedural hypotension and hypoxia. Data were extracted from an electronic medical record and analyzed using SPSS version 20.0. Univariate analysis and stepwise multivariable logistic regression were performed to determine if there was an association between patient comfort and CSI training. Predictors of these outcomes including patient age, gender, sedation use and dosing, procedure completion, quality of bowel preparation, endoscopist experience, and specialty were included in the analysis. RESULTS 2533 colonoscopies were included in the study. The mean dose of sedatives was reduced immediately following CSI training and at 8 months for both Fentanyl (75.4 mcg v. 67.8 mcg v. 65.9 mcg, p < 0.001) and Midazolam (2.57 mg v. 2.27 mg v. 2.19 mg, p < 0.001). The percentage of patients deemed to have a comfortable exam improved following endoscopist participation in CSI training and remained improved at 8 months (55.1% v. 70.2% v. 69.8%, p < 0.001). No significant change in rates of intraprocedural hypoxia or hypotension were noted following CSI training. CONCLUSION CSI training is associated with improved patient comfort and reduced sedation requirements during colonoscopy.
Collapse
Affiliation(s)
- B Evans
- Department of Surgery, Dalhousie University, Halifax, NS, Canada. .,Department of Surgery, Memorial University, St. John's, NL, Canada.
| | - J Ellsmere
- Department of Surgery, Dalhousie University, Halifax, NS, Canada
| | - I Hossain
- Department of Surgery, Memorial University, St. John's, NL, Canada
| | - M Ennis
- Department of Surgery, Memorial University, St. John's, NL, Canada
| | - E O'Brien
- Department of Surgery, Memorial University, St. John's, NL, Canada
| | - L Bacque
- Department of Surgery, Memorial University, St. John's, NL, Canada
| | - M Ge
- Department of Surgery, Memorial University, St. John's, NL, Canada
| | - J Brodie
- Department of Surgery, Memorial University, St. John's, NL, Canada
| | - J Harnett
- Department of Medicine, Memorial University, St. John's, NL, Canada
| | - M Borgaonkar
- Department of Medicine, Memorial University, St. John's, NL, Canada
| | - D Pace
- Department of Surgery, Memorial University, St. John's, NL, Canada
| |
Collapse
|
3
|
Narayan S, Pietrusz A, Allen J, Docherty K, Emery N, Ennis M, Flesher R, Foo W, Freebody J, Gallagher E, Grose N, Harris D, Hewamadduma C, Holmes S, James M, Maidment L, Mayhew A, Moat D, Moorcroft N, Muni-Lofra R, Nevin K, Quinlivan R, Sodhi J, Stuart D, White N, Yvonne J. Adult North Star Network (ANSN): Consensus Document for Therapists Working with Adults with Duchenne Muscular Dystrophy (DMD) - Therapy Guidelines. J Neuromuscul Dis 2022; 9:365-381. [PMID: 35124658 DOI: 10.3233/jnd-210707] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- S Narayan
- University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
| | - A Pietrusz
- UCL Queen Square Institute of Neurology, MRC Centre for Neuromuscular Diseases, UK
| | - J Allen
- Neuromuscular Complex Care Centre (NMCCC), National Hospital for Neurology and Neurosurgery, UK
| | - K Docherty
- University Hospitals Dorset NHS Foundation Trust, UK
| | - N Emery
- The Robert Jones and Agnes Hunt Orthopaedic Hospital, UK
| | - M Ennis
- The Walton Centre NHS Foundation Trust, UK
| | - R Flesher
- The Walton Centre NHS Foundation Trust, UK
| | - W Foo
- Manchester University NHS Foundation Trust, UK
| | - J Freebody
- John Radcliffe Hospital -OxfordUniversity Hospitals NHS Foundation Trust, UK
| | | | - N Grose
- North Bristol NHS Foundation Trust, The South West Neuromuscular Operational Delivery Network (SWNODN), UK
| | - D Harris
- West Midlands Rehabilitation Centre, Birmingham Community Healthcare NHS Foundation Trust, UK
| | - C Hewamadduma
- Sheffield Teaching Hospitals NHS Foundation Trust, UK.,Sheffield Institute for Translational Neurosciences (SITRAN), University of Sheffield, UK
| | - S Holmes
- MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UK
| | - M James
- The John Walton Muscular Dystrophy Research Centre, Newcastle, UK
| | - L Maidment
- Sheffield Teaching Hospitals NHS Foundation Trust, UK
| | - A Mayhew
- The John Walton Muscular Dystrophy Research Centre, Newcastle, UK
| | - D Moat
- The John Walton Muscular Dystrophy Research Centre, Newcastle, UK
| | - N Moorcroft
- West Midlands Rehabilitation Centre, Birmingham Community Healthcare NHS Foundation Trust, UK
| | - R Muni-Lofra
- The John Walton Muscular Dystrophy Research Centre, Newcastle, UK
| | - K Nevin
- Sheffield Teaching Hospitals NHS Foundation Trust, UK
| | - R Quinlivan
- UCL Queen Square Institute of Neurology, MRC Centre for Neuromuscular Diseases, UK
| | - J Sodhi
- The John Walton Muscular Dystrophy Research Centre, Newcastle, UK
| | | | - N White
- The Robert Jones and Agnes Hunt Orthopaedic Hospital, UK
| | - J Yvonne
- University Hospitals of Leicester Emergency and Specialist Medicine, UK
| | | |
Collapse
|
4
|
Wahl K, Ennis M, Jeong D, Knight K, Renner R, Munro S, Dunn S, Guilbert E, Norman WV. POSTER ABSTRACTS. Contraception 2021. [PMCID: PMC8421027 DOI: 10.1016/j.contraception.2021.07.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
5
|
Ennis M, Renner R, Norman WV, Dunn S, Pymar H, Styffe C, Guilbert E. POSTER ABSTRACTS. Contraception 2021. [DOI: 10.1016/j.contraception.2021.07.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Flood M, Ennis M, Ludlow A, Sweeney F, Mellon L, Boland F, de Brún A, Hanratty M, Moriarty F. Using Human-Centred Design to Develop Innovative Approaches to Improve Delivery of Brief Interventions in Primary Care: The HealthEir Project. International Journal of Pharmacy Practice 2021. [PMCID: PMC8083634 DOI: 10.1093/ijpp/riab016.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Introduction A priority action of the Healthy Ireland implementation plan is the Making Every Contact Count initiative (MECC) that aims to leverage the 30 million annual contacts with the healthcare system by asking every health worker to deliver brief interventions [1]. Benefits of brief interventions are well established, but GPs and pharmacists report challenges implementing them in practice including limited training, time, and poor fit with existing practices [2]. Aim This government-funded Sláintecare project aimed to develop a novel method for brief interventions in pharmacy/GP settings using human-centred design. Methods User research was carried out with twelve users, including patients (3), GPs (4), and pharmacists (5) to identify their needs and priorities. Participants were recruited via email using a purposive sampling approach and completed semi-structured interviews with a design researcher. All participants invited agreed to participate. Next, a series of design sprints were completed with the research team. Design sprints allowed the team to integrate insights from user research with findings from a literature review/secondary research to understand pain points, identify stakeholder and user goals, and develop a list of initial design specifications. This list was used to develop and iterate a series of prototype solutions. Prototype service blueprints and wireframes (simple, two-dimensional schematic illustrations of the digital interface) were developed and tested with users before final versions were agreed. Results Findings from the interviews and literature review indicated (1) the main barrier to adoption was time, (2) patients and pharmacists were very positive about brief interventions with GPs more hesitant, (3) an approach blending technology with a consultation was preferred, and (4) having a specific list of local supports was important. Prototyping and evaluation processes identified that a simple interface with a clear indication of progress were preferred. A blended intervention combining a tablet-based digital tool and structured interaction was developed. The interface was designed to maximise use of patient and healthcare professional time, and mapped to the 5As approach (which is underpinned by principles of motivational interviewing, shared-decision making, and readiness to change frameworks). The HealthEir digital tool enables patients to self-complete the Ask, Advise, and Assess phases of a brief intervention using a tablet device while waiting to see their pharmacist/GP. The pharmacist or GP then review the patient’s responses, risk level, and importance confidence and readiness scores. They complete the Assist and Arrange elements during the consultation, supported by a directory of local/national patient support services before printing information tickets for the patient to keep. The HealthEir intervention has been successfully rolled out at eight pilot pharmacy sites nationally, with a mix of urban/rural sites, and independent/chain pharmacies. Conclusions Adopting an interdisciplinary approach based on human-centred design principles led to the development of a blended brief intervention that has been successfully introduced in pilot sites across Ireland. While the implementation has been smooth despite COVID-19 challenges, and initial feedback has been very positive, the impact cannot yet be fully evaluated as research is ongoing. Future work will involve extending the intervention to include other healthcare professionals. References 1. Making Every Contact Count Framework https://www.hse.ie/eng/about/who/healthwellbeing/making-every-contact-count/framework/framework.html (accessed Oct 10, 2020) 2. Keyworth C, Epton T, Goldthorpe J, Calam R, Armitage CJ. ‘It's difficult, I think it's complicated’: Health care professionals’ barriers and enablers to providing opportunistic behaviour change interventions during routine medical consultations. British journal of health psychology. 2019 Sep;24(3):571–92.
Collapse
Affiliation(s)
- M Flood
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - M Ennis
- TU Dublin School of Creative Arts, Technological University Dublin, Dublin, Ireland
| | - A Ludlow
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - F Sweeney
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - L Mellon
- Division of Population Health Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - F Boland
- Data Science Centre, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - A de Brún
- School of Nursing Midwifery and Health Systems, Health Sciences Centre, University College Dublin, Ireland
| | - M Hanratty
- Department of Product Design, National College of Art and Design, Dublin, Ireland
| | - F Moriarty
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| |
Collapse
|
7
|
Goodwin PJ, Ennis M, Cescon DW, Elser C, Haq R, Hamm CM, Lohmann AE, Pimentel I, Chang MC, Dowling RJ, Stambolic V. Abstract P1-16-03: Phase II randomized clinical trial (RCT) of metformin (MET) vs placebo (PLAC) in combination with chemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breast cancer (MBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-16-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MET treatment of diabetes is associated with improved BC outcomes. Hirsch et al (Cancer Res 2009;69:7505-7511) suggested MET may act synergistically with CXT in BC rodent models. We conducted a double-blind Phase II RCT of CXT plus MET vs placebo in LABC/MBC.
Methods: Non-diabetic BC patients (pts) about to commence 1st-4th line CXT (prespecified anthracycline, taxane, vinorelbine, platinum or capecitabine; HER2 Rx permitted) for MBC or refractory LABC (any ER, PgR, HER2) were eligible if (i) age 18-75, (ii) ECOG 0-2, (iii) adequate hepatic, renal, bone marrow, cardiac function and (iv) measurable or evaluable disease. Those with CNS metastases, recent MET use or radiotherapy to target lesions, intake of ≥ 3 alcoholic drinks/day, history of lactic acidosis or current/planned pregnancy or lactation were ineligible. Randomization was to MET 850 mg po bid (or identical PLAC bid) with a 2 day ramp up of one tablet/day; dose was reduced/drug discontinued in a pre-specified manner for grade 2-4 toxicity. Disease status and toxicity/HRQOL were assessed at baseline and q9 weeks until progression. Primary outcome was progression-free survival (PFS); secondary outcomes included survival (OS), response and toxicity. With 40 subjects and type one error 0.2 (1-sided), a PFS HR of 0.58 could be detected with 80% power. PFS was analyzed using Cox proportional hazards regression.
Results: 40 pts were randomized (22 MET, 18 PLAC). Mean age 55.4 vs 56.9 years; ER/PgR+ in 86.4 vs 83.3%; time from 1st metastases to randomization 297 vs 405 days, in MET vs PLAC respectively. MET pts were more likely to have visceral metastases (95.5% vs 72.2% PLAC) and less likely to be HER2+ (9.1% vs 23.5% PLAC). CXT was 1st line in 68.2% MET and 66.7% PLAC pts. Toxicity - # events: Gr 4: 0 MET vs 1 PLAC, Gr 3: 14 MET vs 14 PLAC; Gr 1 or 2: 193 MET (mainly GI) vs 53 PLAC. Best response: PR 18.2% MET vs 22.2% PLAC, SD 31.8% MET vs 11.1% PLAC, PD 45.4% MET vs 50.0% PLAC, P = 0.41. Mean PFS 164 days MET vs 192 days PLAC; HR (MET vs PLAC) 1.14 (95% CI 0.59-2.2), 1-sided p=0.65. Mean OS 645 MET vs 831 PLAC days; HR (MET vs PLAC) 1.6, 95% CI 0.72-3.54, 1-sided p=0.88.
Conclusion: In these BC pts receiving 1st-4th line CXT, MET (vs PLAC) did not improve response rates, PFS or OS. Gr 1 and 2 toxicity was higher with MET than PLAC. These results do not support use of MET with CXT in refractory LABC/MET BC. MA32, an adjuvant trial of MET vs PLAC in early BC will provide information on MET in the adjuvant setting.
Funded by the Breast Cancer Research Foundation (New York) and Hold'em for Life Charity (Toronto)
Citation Format: Goodwin PJ, Ennis M, Cescon DW, Elser C, Haq R, Hamm CM, Lohmann AE, Pimentel I, Chang MC, Dowling RJ, Stambolic V. Phase II randomized clinical trial (RCT) of metformin (MET) vs placebo (PLAC) in combination with chemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-16-03.
Collapse
Affiliation(s)
- PJ Goodwin
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - M Ennis
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - DW Cescon
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - C Elser
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - R Haq
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - CM Hamm
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - AE Lohmann
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - I Pimentel
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - MC Chang
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - RJ Dowling
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - V Stambolic
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| |
Collapse
|
8
|
Jerzak KJ, Cescon DW, Chia SK, Bratman S, Ennis M, Stambolic V, Chang M, Dowling R, Goodwin PJ. Abstract OT1-12-01: Exploration of factors associated with imminent risk of late recurrence in hormone receptor positive breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-12-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Research objectives: To conduct a prospective observational study of patient and tumor-related factors in women with high risk hormone receptor (HR)+/HER2- breast cancer (BC) following at least 5 years of adjuvant hormonal therapy, in order to identify risk factors for imminent recurrence.
Rationale: Many of the life-threatening BC recurrences in women with HR+HER2- BC take place more than 5 years post-diagnosis, often after completion of adjuvant hormonal therapy. The identification of a biomarker(s) for late BC recurrence could lead to interventional trials to evaluate preventive therapies. We will evaluate whether the presence of blood-based biomarkers [(i) Circulating Tumor Cells (CTCs), (ii) circulating tumor DNA (ctDNA), (iii) tumor markers (CA 15-3, CEA)] and patient factors may predict BC recurrence.
Trial design: A prospective cohort of eligible women with previously treated HR+HER2- BC who have not experienced a distant recurrence will be enrolled; patient and circulating factors will be measured annually until distant recurrence or study completion. Host factors (including BMI, lifestyle, medical illness, surgery, trauma and stress, as well as circulating PlGF, VEGF-1 and inflammatory markers) that may contribute to exit of BC cells from dormancy will also be assessed.
The primary outcome is distant BC recurrence. Any BC event, including loco-regional recurrence, new breast or other primary cancer will be evaluated as a secondary endpoint. Outcomes will be ascertained by regular self-report (via annual telephone calls) and/or physician report and confirmed by medical record review.
Key eligibility criteria: i) Diagnosis of ER and/or PR positive (either or both 10% positive), HER2 negative invasive BC, ii) predicted >1.5-2% annual risk of recurrence (T2, T3 or T4 with any N+;T1 N2+; T2N0 or T1 N1 cancers with high risk genomic scores), iii) receipt of adjuvant endocrine therapy for at least 4 years, with discontinuation planned in the next 12 months or completion of endocrine therapy within the last 5 years, iv) prior adjuvant chemotherapy, targeted therapy and bone targeted therapies are allowed provided they have been completed.
Specific aims: 1) Determine if the presence of (i) CTCs, (ii) ctDNA, (iii) CA15-3 and CEA are associated with imminent risk (within 1-2 years) of distant recurrence in the study population. 2) Identify host factors associated with these blood-based biomarkers, as well as clinical outcomes.
Statistical methods: A matched case control design (matching for time since completion of adjuvant hormone therapy, baseline T, N and grade) will be used to investigate associations of key study variables with imminent risk of distant recurrence within the next 1-2 years. Measurements of patients who do versus do not recur will be compared over the 1-2 years prior to relapse. Each variable will be allocated one third of a study-wide type one error of 0.05 (2-sided). ROC analyses and multivariable modelling will be used to optimize sensitivity, specificity, PPV and NPV. Available questionnaire data will be summarized at all time-points to generate descriptive survivorship data.
Accrual: Starting in August 2018, we plan to recruit 1,000 patients over 2 years at selected Canadian cancer centres.
Citation Format: Jerzak KJ, Cescon DW, Chia SK, Bratman S, Ennis M, Stambolic V, Chang M, Dowling R, Goodwin PJ. Exploration of factors associated with imminent risk of late recurrence in hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-12-01.
Collapse
Affiliation(s)
- KJ Jerzak
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - DW Cescon
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - SK Chia
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - S Bratman
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - V Stambolic
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - M Chang
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - R Dowling
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
9
|
Jerzak KJ, Lohmann AE, Ennis M, Nemeth E, Ganz T, Goodwin PJ. Abstract P3-08-08: Prognostic associations of plasma hepcidin in early breast cancer (BC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-08-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Intra-tumor RNA expression of hepcidin has been linked to adverse metastasis-free survival in women with early BC, but the prognostic implications of this inflammatory marker and iron-regulating peptide are unknown.
Methods: Using an ELISA assay, we measured plasma hepcidin in the banked blood of 518 women who were recruited from 1989-1996 for a prospective cohort study regarding diet and lifestyle factors in BC. Blood had been obtained 4-12 weeks post-operatively and prior to treatment with radiation, chemotherapy or hormonal therapy. Women ages 18 to 75 with T1-3, N0-1, M0 BC who underwent surgery and axillary dissection were included; those with metabolic disorders were excluded. Tumor size, grade and ER/PR expression were abstracted from pathology reports; HER2 status was unknown. Median follow-up was 12.1 years (range, 0.2 to 17 years).
Univariable Cox regression models were used to determine the association between hepcidin and i) time to distant BC recurrence (primary outcome), and ii) time to death due to any cause. Multivariable Cox proportional hazards models were adjusted for age (continuous), T stage (T2, T3, Tx vs T1), tumor grade (3 vs 2 or 1), N stage (node positive vs negative), ER/PR expression (both ER and PR negative vs either positive) a-priori. Associations between hepcidin and CRP, IL6, insulin, cholesterol, glucose, vitamin D, total iron, transferrin, and soluble transferrin receptor; sTfR were explored (Pearson's coefficients).
Results: Hepcidin ranged from 4.70-190.70 ng/L (median 16.25; IQR 16.40 ng/L). To ensure normal distribution, a transformed [-1/sqrt (x)] hepcidin variable was used for prognostic analyses. Average age was 50.3±9.7 years. 16% were obese [body mass index (BMI) >30kg/m2], 30% (n=156) were node positive, 35% (n=181) had grade 3 tumors and 71% (n=370) had ER and/or PR positive tumors. 77% underwent a lumpectomy, 73% (n=380) received adjuvant radiotherapy and 39% (n=203) received adjuvant chemotherapy.
Plasma hepcidin was not univariably associated with either time to distant BC recurrence (HR for 75th percentile versus 25th 1.20; 95%CI 0.79-1.32) or time to death due to any cause (HR 1.23; 95%CI 0.95-1.59) in the overall cohort; multivariable results were similar. In pre-planned analyses, the prognostic association of hepcidin differed by BMI (≤30 vs >30 kg/m2; interaction p-values <0.05): among obese women, higher hepcidin was significantly associated with a shorter time to distant BC recurrence in both univariable (HR 1.81; 95%CI 1.06–3.10) and multivariable (HR 1.84; 95%CI 1.04–3.25) models. Higher hepcidin was associated with shorter time to death due to any cause in a univariable model (HR 1.91; 95%CI 1.13–3.22) but not in a multivariable analysis. There was a moderate association between hepcidin and total iron (r=0.35), transferrin (r=0.43) and sTfR (r=-0.39); associations with IL6, CRP and metabolic factors were very weak (r<0.2).
Conclusion: Higher plasma hepcidin was independently associated with a shorter time to distant BC recurrence in obese women but not in the overall cohort. Further investigation of hepcidin and mechanisms linking it to adverse BC outcomes is warranted.
Citation Format: Jerzak KJ, Lohmann AE, Ennis M, Nemeth E, Ganz T, Goodwin PJ. Prognostic associations of plasma hepcidin in early breast cancer (BC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-08-08.
Collapse
Affiliation(s)
- KJ Jerzak
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of California, Los Angeles, Los Angeles, CA
| | - AE Lohmann
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of California, Los Angeles, Los Angeles, CA
| | - M Ennis
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of California, Los Angeles, Los Angeles, CA
| | - E Nemeth
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of California, Los Angeles, Los Angeles, CA
| | - T Ganz
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of California, Los Angeles, Los Angeles, CA
| | - PJ Goodwin
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of California, Los Angeles, Los Angeles, CA
| |
Collapse
|
10
|
Abstract
Abstract
Background Significant sexual dysfunction is reported in women with breast cancer (BC) in the years following diagnosis. It is unclear whether symptoms persist over time in BC survivors (BCS) as long-term data compared to healthy controls is lacking. We compared sexual functioning in long-term BCS to controls and explored the impact of adjuvant therapy on sexual health. Methods A cohort of women with localized BC recruited from 1989 to 1996 was prospectively followed as previously described. BCS without recurrence and controls without BC were contacted between 2005 and 2007 and answered self-reported quality of life questionnaires. Sexual health was measured with the Sexual Activity Questionnaire (SAQ). Vasomotor, gynecological and bladder symptoms were scored using the Menopausal Symptom Scale (scale ranges 0-4) based on the Breast Cancer Prevention Trial Symptom Checklist. Regression analysis was used to compare groups, with and without adjustment for age (quadratic) and menopausal status. P values <0.05 were considered significant. Results 248 of 285 BCS and 159 of 167 controls completed the SAQ. The median time from diagnosis of BCS was 12.5 years. BCS were slightly older (61.9 vs 59.1 years, p=0.0004) and somewhat more likely to be post-menopausal (94.4 vs 85.5%, p=0.0025) than controls. Overall, fewer BCS were sexually active than controls (45.2 vs 59.7%, p=0.0041). This difference was no longer significant when adjusted for age and menopausal status (odds ratio 0.68, p=0.075). In those sexually active, no significant differences were noted on the SAQ Pleasure and Discomfort scales.Differences in adjuvant treatment were not significantly associated with being sexually active or the SAQ subscales. BCS scored higher (worse) on the gynecological and bladder symptom scale than controls (0.66 vs 0.43, p=0.0036, adjusted difference 0.24, p=0.0029; 0.60 vs 0.41, p=0.02, adjusted difference 0.18, p=0.029 respectively), but no difference was seen in vasomotor scores. Gynecological symptom scores were greatest in BCS who received adjuvant chemotherapy. Conclusion Despite more frequent long-term gynecological and bladder symptoms, sexual health is similar in BCS and controls. Adjuvant chemotherapy is associated with persistent gynecological symptoms and interventions aimed at improving these could improve quality of life.
Citation Format: Soldera SV, Ennis M, Lohmann AE, Goodwin PJ. Sexual health in long-term breast cancer survivors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-22.
Collapse
Affiliation(s)
- SV Soldera
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - AE Lohmann
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
11
|
Chang MC, Ennis M, Dowling RJO, Stambolic V, Goodwin PJ. Abstract P6-02-03: Leptin receptor (OB-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background/Aims: Obesity is associated with a 30-50% increased risk of breast-cancer (BC) mortality, most consistently in estrogen receptor (ER) positive disease, through unclear mechanisms. Leptin is a multi-functional protein with key actions on adipose tissue. In pre-clinical studies, leptin stimulates the growth, survival, and progression of BC cells through both estrogen dependent and other (e.g. JAK/STAT, PI3K/Akt, MAPK) pathways. Leptin has also been associated with increased BC risk and poor prognosis. Our aim was to correlate tumor leptin-receptor (OB-R) expression with tissue markers of cell signaling and systemic markers of obesity, inflammation, and metabolism in a cohort of ER+/HER2- BC patients.
Methods: From our biorepository, we identified ER+/HER2- BC patients having both blood and tissue samples available. Data included BMI, menopausal status, and family/cancer/medical history, tumor histology, grade, stage, and ER/PgR/HER2 status. We performed blood assays for factors related to inflammation, tumor growth, hormonal regulation, and metabolism (see below). Immunohistochemistry for OB-R, pAkt (S473), pERK (T202/Y204), and insulin-receptor (IR) was performed on archived tissue, and scored for % positive cells and intensity of staining. Allred and H-scores were calculated. Associations with OB-R scores were calculated using Pearson, Spearman, and χ2 methods.
Results: 129 patients were eligible; 69.8% were post-menopausal and mean BMI was 27.8 ± 6.5 kg/m2. Most tumors were no-special-type (79%), PgR+ (90%), and node-neg (78%). The tissue expression of OB-R and other markers was scorable in 118 (91%) cases.
OB-R was expressed in all 118/118 cancers (Allred score range: 3 to 8; median 7, mean 6.61). High blood leptin did not downregulate OB-R (Spearman R=0), even though leptin was strongly correlated with BMI (Pearson r=0.78, p<0.00001). Increasing OB-R correlated with phosphorylation of Akt (R=0.19) but not ERK (R=0.08). By contrast, high BMI was associated with lower Akt (R=-0.18) and ERK (R=-0.11) phosphorylation.
OB-R correlated with ER (Spearman R = 0.27), PgR (R=0.29), and insulin receptor (R = 0.24), weakly correlated with estradiol (Spearman, R=0.11) and fasting glucose (R=0.18), and negatively correlated with systemic IL-2 (R=-0.11) and IL-6 (R=-0.21). OB-R was not correlated with other blood markers (insulin, HOMA, PAI-1, IL-1ẞ, IL-8, VEGF, EGF, TNF-α,hsCRP, SHBG, or estrogens) or tumor grade.
Conclusions: OB-R is highly expressed in breast tumor tissue even in non-obese patients. Although leptin and BMI did not modulate OB-R expression, downstream signaling (e.g. Akt, ERK) did show a BMI-dependent effect, albeit of limited magnitude. This suggests that leptin acts on breast cancer cells through OB-R activation and downstream Akt/ERK signaling, without a coupled change in total OB-R expression. Further work is needed to elucidate the roles of inflammation, estrogens, and regulatory mechanisms within the PI3K-PTEN and Ras-MAPK cell-signaling networks.
The authors wish to acknowledge the generous support of the Breast Cancer Research Foundation and Hold'Em For Life Charity Challenge.
Citation Format: Chang MC, Ennis M, Dowling RJO, Stambolic V, Goodwin PJ. Leptin receptor (OB-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-02-03.
Collapse
Affiliation(s)
- MC Chang
- Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - RJO Dowling
- Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - V Stambolic
- Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| |
Collapse
|
12
|
Dowling RJ, Niraula S, Chang MC, Ennis M, Stambolic V, Goodwin PJ. Abstract P1-02-03: Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant metformin. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Numerous clinical studies have reported that diabetic patients receiving metformin exhibit decreased cancer incidence and cancer related mortality. Metformin's mechanism of anti-tumor action has been attributed to both direct effects on cancer cells and systemic changes in insulin metabolism. Indeed, metformin reduces circulating insulin levels, which may be integral to its effectiveness in the breast cancer (BC) setting where hyperinsulinemia is associated with both recurrence and death. While the impact of metformin on blood glucose and insulin is well documented, its effects on other systemic physiologic and inflammatory factors are unknown. We completed a neoadjuvant "window of opportunity" study of metformin in non-diabetic women with BC and a series of analyses were performed on plasma samples to assess the impact of metformin on circulating inflammatory markers, growth factors, and tumor associated antigens.
Methods: Non-diabetic women with early stage, untreated BC were given metformin 500 mg tid for ≥2 weeks post diagnostic core biopsy until surgery. Fasting blood was collected at diagnosis and surgery to assess circulating markers pre- and post-metformin administration. Plasma was isolated from blood samples and evaluated for CRP, TNF-alpha, IL-6, IL-8, VEGF, EGF, PlGF (placenta growth factor), CA15-3, and SHBG (sex hormone binding globulin). Change scores (post-metformin minus pre-) were calculated and the degree of change characterized by the median change and the rank-biserial correlation. The Wilcoxon signed-rank test was used to test the null hypothesis that the change scores were symmetrically distributed around zero versus more positive or negative change.
Results: A total of 39 patients (mean age 51 years) completed the study and received metformin for a median of 18 days (range 13-40). Metformin was associated with changes in the levels of growth factors, with increases seen in EGF (median increase 1.1 pg/mL, r=0.42, p=0.027) and VEGF (1.7 pg/mL, r=0.31, p=0.09). A reduction in PlGF levels (-0.18 pg/mL, r=-0.6, p=0.0028) was also observed. The tumor associated antigen CA15-3 was significantly reduced after metformin treatment (-0.4 pg/mL, r=-0.56, p=0.0024) and a marker of sex hormone bioavailability (SHBG) was increased (2 nM, r=0.30, p=0.1). For circulating inflammatory markers, a significant increase in the levels of IL-8 (0.8 pg/mL, r=0.36, p=0.048) was observed, but changes in TNF-alpha and IL-6 were minimal (TNF-alpha 0.2 pg/mL, r=0.20, p=0.29; IL-6 0.1 pg/mL, r=0.14, p=0.46) and no change was seen in CRP (0 mg/L, r=-0.05, p=0.93).
Conclusions: Short-term metformin administration was associated with alterations in systemic physiologic and inflammatory factors. Such increases in circulating cytokines and growth factors indicate possible alterations in the inflammatory state of the host and/or tumor. Of note, the reduction seen in the tumor antigen CA15-3 may reflect a disease-modifying effect of metformin in BC.
The authors wish to acknowledge the generous support of the Hold'Em For Life Charity Challenge and the Breast Cancer Research Foundation.
Citation Format: Dowling RJ, Niraula S, Chang MC, Ennis M, Stambolic V, Goodwin PJ. Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant metformin [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-03.
Collapse
Affiliation(s)
- RJ Dowling
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Pathology and Laboratory Medicine, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - S Niraula
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Pathology and Laboratory Medicine, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - MC Chang
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Pathology and Laboratory Medicine, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - M Ennis
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Pathology and Laboratory Medicine, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - V Stambolic
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Pathology and Laboratory Medicine, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - PJ Goodwin
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Pathology and Laboratory Medicine, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| |
Collapse
|
13
|
Einarsson GG, Comer DM, McIlreavey L, Parkhill J, Ennis M, Tunney MM, Elborn JS. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax 2016; 71:795-803. [PMID: 27146202 DOI: 10.1136/thoraxjnl-2015-207235] [Citation(s) in RCA: 129] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2015] [Accepted: 03/21/2016] [Indexed: 12/16/2022]
Abstract
RATIONALE The role bacteria play in the progression of COPD has increasingly been highlighted in recent years. However, the microbial community complexity in the lower airways of patients with COPD is poorly characterised. OBJECTIVES To compare the lower airway microbiota in patients with COPD, smokers and non-smokers. METHODS Bronchial wash samples from adults with COPD (n=18), smokers with no airways disease (n=8) and healthy individuals (n=11) were analysed by extended-culture and culture-independent Illumina MiSeq sequencing. We determined aerobic and anaerobic microbiota load and evaluated differences in bacteria associated with the three cohorts. Culture-independent analysis was used to determine differences in microbiota between comparison groups including taxonomic richness, diversity, relative abundance, 'core' microbiota and co-occurrence. MEASUREMENT AND MAIN RESULTS Extended-culture showed no difference in total load of aerobic and anaerobic bacteria between the three cohorts. Culture-independent analysis revealed that the prevalence of members of Pseudomonas spp. was greater in the lower airways of patients with COPD; however, the majority of the sequence reads for this taxa were attributed to three patients. Furthermore, members of Bacteroidetes, such as Prevotella spp., were observed to be greater in the 'healthy' comparison groups. Community diversity (α and β) was significantly less in COPD compared with healthy groups. Co-occurrence of bacterial taxa and the observation of a putative 'core' community within the lower airways were also observed. CONCLUSIONS Microbial community composition in the lower airways of patients with COPD is significantly different to that found in smokers and non-smokers, indicating that a component of the disease is associated with changes in microbiological status.
Collapse
Affiliation(s)
- G G Einarsson
- Halo, Queen's University Belfast, Belfast, UK Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - D M Comer
- Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | | | - J Parkhill
- Pathogen Genomics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
| | - M Ennis
- Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - M M Tunney
- Halo, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK
| | - J S Elborn
- Halo, Queen's University Belfast, Belfast, UK Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| |
Collapse
|
14
|
Cescon DW, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, Rao L, Stambolic V, Sridhar S, Goodwin PJ. Abstract P5-12-02: Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Some studies have suggested that women with high BMI have less benefit from aromatase inhibitors (AI) vs. tamoxifen as adjuvant treatment for early breast cancer. One possible mechanism for this observation is that complete suppression of estrogen is not achieved in these women with the standard flat dose of AI. We evaluated whether a doubling of letrozole to 5 mg/day for 4 weeks affected residual estrogen levels in this population.
Methods: Post-menopausal women with early breast cancer and BMI>25 already taking adjuvant letrozole for at least 3 months were recruited from medical oncology clinics at 4 sites in Toronto, Canada. Fasting blood samples were collected 24 hours following the last dose at baseline (routine use of own letrozole), after 28 days of monitored adherence to a provided supply of letrozole (Femara) 2.5 mg/day (Part A), and after an additional 28 days of letrozole (Femara) 5 mg/day (Part B). Symptom/quality of life questionnaires were completed at the same timepoints. Estradiol and estrone were measured using a high sensitivity liquid chromatography-tandem mass spectrometry assay. One interim analysis for futility and efficacy was planned after 31 eligible patients had completed the study, using estradiol and O'Brien-Fleming boundaries with an inner wedge.
Results: 36 patients were enrolled and started on study, and 31 eligible patients completed Parts A and B. The 5 non-completers withdrew because of adverse events (n=4, unlikely related to drug) or withdrawal of consent (n=1). Median age was 62 (range 48 to 77) and BMI 28.3 kg/m2 (Range 25.2 to 42.2 kg/m2). One patient had non-postmenopausal estrogen levels at Day 29 and Day 57 and one patient's blood assay was unsuccessful; both were excluded from further analyses. The predetermined stopping rule for futility was met. Estradiol levels (mean±standard deviation) changed from 2.68±0.40 pg/mL at baseline to 2.67±0.59 pg/mL at Day 29 to 2.70±0.53 pg/mL at Day 57. Mean change from Day 29 to Day 57 was 0.03±0.48 pg/mL (95% confidence interval -0.15 to 0.21 pg/mL). Four patients reported new or increased arthralgias (to NCI CTCAE Grade 2 or 3) while taking letrozole 5 mg/day in Part B. There was no association between changes in estradiol levels and either study non-completion or the development of arthralgias. Estrone results were similar.
Conclusion: Increasing letrozole from 2.5 to 5 mg/day did not further suppress estrogen levels in women with BMI>25. It is unlikely that letrozole dosing tailored to body size would improve clinical outcomes. The letrozole 5 mg/day intervention was terminated based on the results of the interim analysis for futility.
Citation Format: Cescon DW, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, Rao L, Stambolic V, Sridhar S, Goodwin PJ. Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-02.
Collapse
Affiliation(s)
- DW Cescon
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - C Townsley
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - D Warr
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - C Elser
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - L Rao
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - V Stambolic
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - S Sridhar
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| |
Collapse
|
15
|
Chang MC, Eslami Z, Ennis M, Goodwin PJ. Abstract P5-05-01: Prevalance of crown-like structures of the breast, a histologic biomarker linked to obesity: A retrospective study of 99 cases. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-05-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Breast cancer risk is multifactorial, and depends partly on obesity and related metabolic imbalances, including inflammation. Obesity is increasing worldwide, and is a known cancer risk albeit with complex mechanisms. Previous reports (Morris et al., 2011; Iyengar et al., 2015) indicate that local inflammation can be seen histologically as a rings of macrophages around necrotic adipocytes ("crown-like structures of the breast", CLS-B). Our goal was to determine the prevalence of CLS-B in routine specimens from a cohort of patients with known BMI.
Methods: We retrieved archival H&E slides from a breast cancer cohort (N=99) previously characterized for BMI and fasting plasma/serum metabolic factors. Two pathologists reviewed all available sections of white adipose tissue not adjacent to tumour (median 7 blocks/case), excluding fat necrosis and mastitis, blinded to correlative data/BMI. We recorded the presence/absence and numbers of CLS-B, defined as a continuous ring of macrophages surrounding an adipocyte. Paraffin blocks were available in a subset (N=72) and a representative block was immunostained for CD68 to highlight CLS-B. For all cases, the average fat vacuole size was determined by digital image analysis (NIH ImageJ Software). We performed correlative statistics between CLS-B status and clinical data (χ2, Wilcoxon rank-sum tests).
Results: CLS-B were present in 37 of 99 cases (37%). When present the total number of CLS-B ranged from 1 to 18 (mean=4.3, median=3). CLS-B were detected in 7/10 (70%) patients with BMI >30 vs. 30/89 (34%) with BMI ≤ 30 (p=0.02). CLS-B also trended to higher prevalence in women over 60 compared to women under 60 (12/20, 60% vs. 25/79, 32%, p = 0.063). There was no significant association of CLS-B status with tumor T- and N-stage or grade (all P>0.4). The median C-reactive protein in the group with CLS-B was 1.5 mg/L vs. 0.8 mg/L in the group without CLS-B (P=0.10) There was no significant association of CLS-B with insulin, glucose, HOMA, leptin, adiponectin, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, or IGF-1 (all P>0.27). The average fat globule area determined by image analysis correlated significantly with BMI (Spearman correlation 0.54, p<0.0001) but not to the presence of CLS-B (p=0.102).
Within the subset immunostained for CD68, 32/72 (44%) had CLS-B on the original H&E sections, whereas 13/72 (18%) had CLS-B on the representative CD68-stained section. This corresponded to a false negative in 22/59 (37%) CD68-negative cases, and increased detection in 3/13 of the CD68-positive cases.
Conclusion: In our cohort, obesity is correlated with elevated tissue inflammation as seen by the presence of CLS-B, but CLS-B is not correlated with metabolic markers. CLS-B are well appreciated on routine H&E sections; however, more work is needed to find a practical approach to both ancillary testing (e.g. CD68) and quantitation. Our work independently confirms the association of CLS-B with obesity, and supports the concept that CLS-B is a tissue biomarker of obesity-related inflammation.
(Z.E. was co-principal author.)
Citation Format: Chang MC, Eslami Z, Ennis M, Goodwin PJ. Prevalance of crown-like structures of the breast, a histologic biomarker linked to obesity: A retrospective study of 99 cases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-05-01.
Collapse
Affiliation(s)
- MC Chang
- Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - Z Eslami
- Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - M Ennis
- Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| | - PJ Goodwin
- Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada
| |
Collapse
|
16
|
Lohmann AE, Chang M, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazae K, Stambolic V, Goodwin PJ. Abstract P2-02-12: Association of inflammatory and tumor markers with circulating tumor cells in metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Circulating tumor cells (CTCs) are associated with prognosis in metastatic breast cancer (BC). We evaluated the association of inflammatory/tumor markers and CTCs in women with progressing metastatic breast cancer prior to commencing a new line of systemic therapy.
Methods: From February 2013 to April 2015, 96 patients with metastatic BC about to start a new treatment (due to progression), without current diabetes or use of anti-inflammatory agents, were recruited from four Ontario cancer hospitals. Women provided fasting blood for inflammatory and tumor markers and CTC measurement; CTCs were assayed within 72 hours of collection using CellSearch. Blood was frozen at -80C until assays were performed in a single batch (C-reactive protein (CRP), IL-6, PAI-1, Ca15-3, Ca125, VEGF, TNFa). Associations of CTCs with blood factors were evaluated using Pearson correlation coefficients after transforming the variables to normality. For CTCs the transformation log(x+0.5) was used. Associations with categorical variables were tested using one-way analysis of variance. P values <0.05 were significant.
Results: Median age of patients was 60.5 years, 87 (90.6%) were post-menopausal, 83 (86.5%) had hormone receptor positive BC, 16 (16.7%) HER2 positive BC, 10 (10.4%) triple negative; 75 (78.1%) grade II/III. At the time of CTC measurement, bone, lung, liver and brain metastases were present in 79%, 44%, 40% and 6% of patients respectively, with 54%, 37%, 35% and 3% having progression at these sites respectively. PAI-1 and CA15-3 exceeded the limit of the assay in 11 and 5 cases respectively (the upper limit of the assay was used in the analysis). 33.4% of patients were starting first line therapy, 25% second line and 16.7% third line. CTC counts (per 7.5cc) ranged from 0 to 1238 (median 2, geometric mean 3.63); none were detected in 29 (30.2%) patients, 1 to 4 in 25 (26%) and 5 or more in 42 (43.8%) patients. CTCs were not associated with age, estrogen receptor, progesterone receptor, HER2, line of treatment, lymph-vascular invasion or tumor grade. Compared to metastatic disease at other sites, CTCs were higher in the presence of bone (p=0.027) and liver metastases (p=0.002) and with progressing bone (p=0.018) and liver (p=0.012) metastases. CTCs were significantly associated with CRP (R =0.25, p=0.014), IL-6 (R=0.31, p=0.002), PAI-1 (R=0.31, p=0.002), Ca15-3 (R=0.44, p=<0.0001) and Ca 125 (R=0.21, p=0.04) but not with VEGF and TNFa (R = 0.11, p= 0.29 and R = 0.16, p=0.11, respectively).
Conclusion: CTCs were associated with bone and liver metastases and with higher levels of inflammatory and tumor markers, potentially reflecting tumor burden. Additional inflammatory marker assays are underway. Future studies are warranted to confirm these findings.
Citation Format: Lohmann AE, Chang M, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazae K, Stambolic V, Goodwin PJ. Association of inflammatory and tumor markers with circulating tumor cells in metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-12.
Collapse
Affiliation(s)
- AE Lohmann
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - M Chang
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - RJO Dowling
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - M Ennis
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - E Amir
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - C Elser
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - C Brezden-Masley
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - T Vandenberg
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - E Lee
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - K Fazae
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - V Stambolic
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| | - PJ Goodwin
- Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada
| |
Collapse
|
17
|
Dowling RJO, Chang MC, Lohmann AE, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin PJ. Abstract P2-02-09: Obesity associated factors are inversely associated with circulating tumor cells in metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Elevated levels of circulating tumor cells (CTCs) are associated with adverse outcomes in metastatic breast cancer (BC). However, relationships between CTCs and various patient-related factors that may impact outcome remain undefined. Consequently, associations of CTC counts with obesity and metabolic factors were evaluated in order to gain insight into potential interactions between patient physiology and disease burden. We hypothesized that obesity and associated metabolic factors would be associated with higher CTC counts.
Methods: Non-diabetic women with metastatic BC beginning a new line of treatment due to progressive disease were recruited from four Ontario cancer hospitals between February 2013 and April 2015. Patients provided blood for CTC analysis, which was completed within 72 hours of collection using the Janssen CellSearch platform. Fasting serum was also collected for assessment of metabolic factors including glucose (mmol/L), insulin (pmol/L), leptin (ng/mL) and adiponectin (ng/mL). Associations of CTC counts with these factors, as well as anthropometric measurements (height (cm), weight (kg), BMI (kg/m2)) were evaluated using Pearson correlation coefficients after transforming the variables involved to normality. For CTC counts, the log transformation with half integer correction was used.
Results: 96 patients with a median age of 60.5 years completed the study. Most were post-menopausal (87, 90.6%) and exhibited grade II/III tumors (75, 78.1%). The majority of patients had hormone receptor positive disease (83, 86.5%), but 16.7% (16) were HER2 positive and 10.4% (10) were triple negative. The number of CTCs observed ranged from 0 to 1238 (median 2, geometric mean 3.63). No CTCs were detected in 29 patients (30.2%), whereas 25 patients (26 %) exhibited counts of 1 to 4 CTCs and 42 (43.8%) had 5 or more CTCs. CTCs were not significantly associated with tumor characteristics including ER/PgR, HER2, grade, stage (T/N) or lymphovascular invasion. The number of CTCs inversely correlated with BMI (r=-0.26, p=0.01), leptin (r=-0.29, p=0.004), and leptin-adiponectin ratio (r=-0.3, p=0.004). A similar trend that approached significance was noted for body weight (r=-0.19, p=0.07), insulin (r=-0.19, p=0.06) and homeostatic model assessment (HOMA, an estimate of insulin resistance, r=-0.2, p=0.055). Conversely, adiponectin (r=0.18, p=0.07) and height (r=0.18, p=0.07) were positively associated with CTC counts in correlations that neared significance. No associations were observed for age (r=0.09, p=0.4) or glucose (r=-0.09, p=0.4).
Conclusions: Obesity associated metabolic factors including weight, BMI, insulin, HOMA and leptin were inversely associated (and adiponectin and height positively associated) with CTC counts. These patterns are consistent with weight loss and/or cachexia in women with elevated CTC counts who have higher disease burden. Additional analyses are underway to further characterize these associations and include assessment of serum albumin, free fatty acids, creatine kinase and hepcidin.
Citation Format: Dowling RJO, Chang MC, Lohmann AE, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin PJ. Obesity associated factors are inversely associated with circulating tumor cells in metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-09.
Collapse
Affiliation(s)
- RJO Dowling
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - MC Chang
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - AE Lohmann
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - E Amir
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - C Elser
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - C Brezden-Masley
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - T Vandenberg
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - E Lee
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - K Fazaee
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - V Stambolic
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mt. Sinai Hospital, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; London Regional Cancer Program, University of Western Ontario, London, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| |
Collapse
|
18
|
Reihill JA, Malcomson B, Bertelsen A, Cheung S, Czerwiec A, Barsden R, Elborn JS, Dürkop H, Hirsch B, Ennis M, Kelly C, Schock BC. Induction of the inflammatory regulator A20 by gibberellic acid in airway epithelial cells. Br J Pharmacol 2015; 173:778-89. [PMID: 26013851 DOI: 10.1111/bph.13200] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2014] [Revised: 05/12/2015] [Accepted: 05/14/2015] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND AND PURPOSE NF-κB-driven inflammation is negatively regulated by the zinc finger protein A20. Gibberellic acid (GA3 ) is a plant-derived diterpenoid with documented anti-inflammatory activity, which is reported to induce A20-like zinc finger proteins in plants. Here, we sought to investigate the anti-inflammatory effect of GA3 in airway epithelial cells and determine if the anti-inflammatory action relates to A20 induction. EXPERIMENTAL APPROACH Primary nasal epithelial cells and a human bronchial epithelial cell line (16HBE14o-) were used. Cells were pre-incubated with GA3 , stimulated with Pseudomonas aeruginosa LPS; IL-6 and IL-8 release, A20, NF-κB and IκBα expression were then evaluated. To determine if any observed anti-inflammatory effect occurred via an A20-dependent mechanism, A20 was silenced using siRNA. KEY RESULTS Cells pre-incubated with GA3 had significantly increased levels of A20 mRNA (4 h) and protein (24 h), resulting in a significant reduction in IL-6 and IL-8 release. This effect was mediated via reduced IκBα degradation and reduced NF-κB (p65) expression. Furthermore, the anti-inflammatory action of GA3 was abolished in A20-silenced cells. CONCLUSIONS AND IMPLICATIONS We showed that A20 induction by GA3 attenuates inflammation in airway epithelial cells, at least in part through its effect on NF-κB and IκBα. GA3 or gibberellin-derived derivatives could potentially be developed into anti-inflammatory drugs for the treatment of chronic inflammatory diseases associated with A20 dysfunction.
Collapse
Affiliation(s)
- J A Reihill
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - B Malcomson
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - A Bertelsen
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - S Cheung
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - A Czerwiec
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - R Barsden
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - J S Elborn
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - H Dürkop
- Institute für Pathodiagnostik, Berlin, Germany
| | - B Hirsch
- Charité-University, Institute of Pathology, Berlin, Germany
| | - M Ennis
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| | - C Kelly
- Northern Ireland Centre for Stratified Medicine, University of Ulster, Londonderry, UK
| | - B C Schock
- Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
| |
Collapse
|
19
|
Sturman G, Barrett K, Carruthers N, Ennis M, Pearce FL, Bell D, Chazot PL, Gibbs B. The European Histamine Research Society 44th Annual Meeting, May 6-9, 2015 Malaga, Spain. Inflamm Res 2015; 64 Suppl 1:S1-50. [PMID: 26160655 DOI: 10.1007/s00011-015-0842-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Wen H, McCaughan J, Schock B, Reid A, Rendall J, Elborn J, Downey D, Ennis M, Moore J. 87 Detection of enterotoxins (A–E) from Staphylococcus aureus isolated from CF sputum: Clinical significance of enterotoxigenic (ET+) strains of S. aureus in paediatric and adult CF patients. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30264-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Somma T, Cinci L, Formicola G, Pini A, Thurmond R, Ennis M, Bani D, Masini E. A selective antagonist of histamine H₄ receptors prevents antigen-induced airway inflammation and bronchoconstriction in guinea pigs: involvement of lipocortin-1. Br J Pharmacol 2014; 170:200-13. [PMID: 23734568 DOI: 10.1111/bph.12264] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2012] [Revised: 05/20/2013] [Accepted: 05/24/2013] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND AND PURPOSE Among the pathogenic mechanisms of asthma, a role for oxidative/nitrosative stress has been well documented. Recent evidence suggests that histamine H₄ receptors play a modulatory role in allergic inflammation. Here we report the effects of compound JNJ 7777120 (JNJ), a selective H4 receptor antagonist, on antigen-induced airway inflammation, paying special attention to its effects on lipocortin-1 (LC-1/annexin-A1), a 37 kDA anti-inflammatory protein that plays a key role in the production of inflammatory mediators. EXPERIMENTAL APPROACH Ovalbumin (OA)-sensitized guinea pigs placed in a respiratory chamber were challenged with antigen. JNJ (5, 7.5 and 10 mg.kg⁻¹) was given i.p. for 4 days before antigen challenge. Respiratory parameters were recorded. Bronchoalveolar lavage (BAL) fluid was collected and lung specimens taken for further analyses 1 h after antigen challenge. In BAL fluid, levels of LC-1, PGD2 , LTB4 and TNF-α were measured. In lung tissue samples, myeloperoxidase, caspase-3 and Mn-superoxide dismutase activities and 8-hydroxy-2-deoxyguanosine levels were measured. KEY RESULTS OA challenge decreased LC-1 levels in BAL fluid, induced cough, dyspnoea and bronchoconstriction and increased PGD2 , LTB4 and TNF-α levels in lung tissue. Treatment with JNJ dose-dependently increased levels of LC-1, reduced respiratory abnormalities and lowered levels of PGD2 , LTB4 and TNF-α in BAL fluid. CONCLUSIONS AND IMPLICATIONS Antigen-induced asthma-like reactions in guinea pigs decreased levels of LC-1 and increased TNF-α and eicosanoid production. JNJ pretreatment reduced allergic asthmatic responses and airway inflammation, an effect associated with LC-1 up-regulation.
Collapse
Affiliation(s)
- T Somma
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Reihill J, Malcomson B, Barsden R, Elborn J, Kelly C, Ennis M, Schock B. 111 Defective A20 signalling in cystic fibrosis: anti-inflammatory action of gibberellin. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60247-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Barsden R, Elborn J, Schock B, Ennis M, Kelly C, Zhang SD. 110 Connectivity mapping: an advanced bioinformatics approach to predict A20-inducing small molecules to reduce inflammation. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60246-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Rowan S, Bradley J, Bradbury I, Lawson J, Lynch T, O'Neill K, Ennis M, Elborn JS. P106 Lung Clearance Index is a Repeatable Test of Lung Function and Superior Predictor of CT Scan Abnormalities in Bronchiectasis. Thorax 2013. [DOI: 10.1136/thoraxjnl-2013-204457.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Dowling RJO, Niraula S, Chang MC, Done SJ, Ennis M, Hood N, McCready DR, Leong W, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V. Abstract PD03-05: Analysis of tumour cell signaling in response to neoadjuvant metformin in women with early stage breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd03-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The anti-diabetic drug metformin, commonly used to treat type 2 diabetes due to its ability to reduce circulating glucose and insulin, has emerged as a potential anti-cancer agent. Observational studies have reported decreased cancer incidence and mortality in diabetics receiving metformin. Metformin's ability to reduce insulin may be particularly important for breast cancer (BC) because hyperinsulinemia is an adverse prognostic factor and most cells express the insulin receptor (IR). The anti-cancer effects of metformin are associated with both direct (insulin-independent) and indirect (insulin-dependent) actions. Direct effects are linked to activation of AMPK and an inhibition of mTOR signalling, while indirect effects are mediated by reductions in circulating insulin levels, leading to reduced IR-activated PI3K signalling. We conducted a neoadjuvant, single arm, “window of opportunity” trial examining the clinical and biological effects of metformin on thirty-nine locoregional BC patients awaiting definitive surgery.
Methods: Non-diabetic women with newly diagnosed, untreated BC were given metformin 500 mg tid for ≥2 weeks post diagnostic core biopsy until surgery. Fasting blood and tumour samples were collected at diagnosis and surgery. Blood glucose and insulin were assayed to assess the physiologic effects of metformin, while IHC analysis of tumours was used to characterize cellular markers before and after metformin. Specifically, IR levels and the phosphorylation status of proteins involved in AMPK and PI3K/AKT/mTOR signalling, including AMPK (T172) and AKT (S473), were examined.
Results: 39 patients with a mean age of 51 years received metformin for a median of 18 days (range 13–40) with minor GI toxicities. The clinical effects (previously reported) included significant (p < 0.05) decreases in body mass index (−0.5 kg/m2), weight (−1.2 kg), glucose (−0.14 mM) and HOMA (an estimate of insulin resistance, −0.21), and a decrease in insulin (−4.7 pmol/L) that approached significance (p = 0.0686). Ki67 staining in tumour tissue decreased significantly and TUNEL increased significantly. Levels of IR expression decreased significantly (from 4.39 to 3.82, p = 0.0375) as did the phosphorylation status of AKT (S473) and AMPK (T172) (from 9.82 to 7.08, p = <0.0001; from 6.2 to 5.1, p = 0.0034, respectively).
Conclusions: Metformin impact was consistent with beneficial anti-cancer effects. Reduced AKT phosphorylation, coupled with decreased insulin and IR levels, suggest insulin-dependent effects are important in the clinical setting. Assessment of additional factors in BC cells, including OCT1 expression (required for metformin uptake), and the phosphorylation of ACC (a marker of AMPK activation), is underway and will be reported. Integrated analysis of these factors combined with the physiological and molecular data described above will further enhance understanding of metformin action in the clinical setting.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD03-05.
Collapse
Affiliation(s)
- RJO Dowling
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - S Niraula
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - MC Chang
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - SJ Done
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - M Ennis
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - N Hood
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - DR McCready
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - W Leong
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - JM Escallon
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - M Reedijk
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - PJ Goodwin
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| | - V Stambolic
- Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
| |
Collapse
|
26
|
Comer D, Ennis M, Elborn JS. S87 Differential Inflammatory Responses of Primary Bronchial Epithelial Cells from Subjects with COPD, Healthy Smokers and Never Smokers: Abstract S87 Table 1. Thorax 2012. [DOI: 10.1136/thoraxjnl-2012-202678.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Comer D, Elborn JS, Ennis M. P251 The Role of Reactive Oxidative Species Within Cigarette Smoke Extract on Apoptosis and Inflammation in Primary Nasal Epithelial Cells: Abstract P251 Table 1. Thorax 2012. [DOI: 10.1136/thoraxjnl-2012-202678.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Ennis M. PO83 Beyond statistics: how analysing blog narratives enhances nursing's understanding of the survivorship experience of younger women with breast cancer. Breast 2012. [DOI: 10.1016/s0960-9776(12)70090-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
29
|
de Courcey F, Zholos AV, Atherton-Watson H, Williams MTS, Canning P, Danahay HL, Elborn JS, Ennis M. Development of primary human nasal epithelial cell cultures for the study of cystic fibrosis pathophysiology. Am J Physiol Cell Physiol 2012; 303:C1173-9. [PMID: 23015550 DOI: 10.1152/ajpcell.00384.2011] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Cultured primary epithelial cells are used to examine inflammation in cystic fibrosis (CF). We describe a new human model system using cultured nasal brushings. Nasal brushings were obtained from 16 F508del homozygous patients and 11 healthy controls. Cells were resuspended in airway epithelial growth medium and seeded onto collagen-coated flasks and membranes for use in patch-clamp, ion transport, and mediator release assays. Viable cultures were obtained with a 75% success rate from subjects with CF and 100% from control subjects. Amiloride-sensitive epithelial Na channel current of similar size was present in both cell types while forskolin-activated CF transmembrane conductance regulator current was lacking in CF cells. In Ussing chambers, cells from CF patients responded to UTP but not to forskolin. Spontaneous and cytomix-stimulated IL-8 release was similar (stimulated 29,448 ± 9,025 pg/ml; control 16,336 ± 3,308 pg/ml CF; means ± SE). Thus nasal epithelial cells from patients with CF can be grown from nasal brushings and used in electrophysiological and mediator release studies in CF research.
Collapse
Affiliation(s)
- F de Courcey
- Centre for Infection and Immunity, Queen’s University Belfast, Health Sciences Building, Belfast, UK
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Moffitt K, Martin S, Wei L, Jones A, Webb A, Tunney M, Ennis M, Elborn J. 140 Association between host immunological and pro-inflammatory mediators with survival in cystic fibrosis patients chronically colonised with Pseudomonas aeruginosa (PA). J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60310-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Kelly C, Williams M, Mitchell K, Elborn J, Ennis M, Schock B. WS11.7 Expression of the NF-κB inhibitor A20 is altered in the cystic fibrosis epithelium. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60081-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Kelly C, Canning P, Buchanan P, Williams M, Elborn J, Ennis M, Schock B. WS9.8 Toll like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60067-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Hsu T, Ennis M, Hood N, Goodwin PJ. PD04-09: Self-Reported Cognitive Attributes and Fatigue Improve over Long-Term Follow-Up in Breast Cancer Survivors; Some Cognitive Attributes Are Worse in Breast Cancer Survivors Than in Non-Cancer Controls. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd04-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cognitive deficits and fatigue have been reported in breast cancer (BC) patients undergoing a variety of treatments, including chemotherapy; in some studies these concerns persist after completion of treatment. We examined these factors over time (median 11 yrs) in a longitudinal study of BC patients and compared the status of long-term BC survivors to non-BC controls.
Methods: 535 T1-3, N0-1, M0 BC patients were enrolled 1989–96; 260 women survived without metastases to participate in long-term follow-up (LTFU) measurements in 2006–8. 161 controls without BC were enrolled 2007–8. Questionnaires examined a range of QOL attributes; here we focus on items related to cognition and fatigue including: EORTC QLQ C30 (cognitive functioning, fatigue), Profile of Mood States (POMS — confusion/bewilderment, fatigue/inertia, vigor/activity), Fatigue Symptom Inventory (FSI — average fatigue past week, total disruption index), Everyday Problems (EDP — forgetfulness, difficulty concentrating, easily distracted). 166 of the BC patients had also completed EORTC and POMS at diagnosis and 1 year, and change in items on these questionnaires was calculated. Age and income adjusted differences between BC (LTFU) and controls were analyzed. Clinical significance was defined as ≥5% of the scale range or an effect size of ≥0.2 and statistical significance as P≤ 0.05.
Results: BC cases were older than controls (62.3 vs 59.1 yr), had lower education (24.6 vs 10.2% high school only) and family income (38.2 vs 19.8% < $60,000 annually) (all P<0.01). Cognitive attributes: BC patients showed clinically and statistically significant improvements between diagnosis and LTFU on POMS confusion/bewilderment but not EORTC cognitive functioning. Comparing BC (LTFU) to controls, in multivariate analyses adjusted for age and income, EORTC cognitive functioning (81.5 vs 87.4) and EDP forgetfulness (0.9 vs 0.6) were clinically and statistically significantly worse in BC patients than controls. In contrast, POMS confusion/bewilderment, EDP difficulty concentrating and EDP easily distracted scores were similar in BC patients at LTFU and controls. Fatigue: BC patients showed clinically and statistically significant improvements between diagnosis and LTFU on EORTC fatigue, POMS fatigue/inertia and POMS vigor/activity. After adjustment for age and income there were no clinically and statistically significant differences between BC (LTFU) and controls on any fatigue items.
Conclusions: Fatigue items, as well as some cognitive items, improved over time in BC patients and scores were comparable to scores in non-BC controls at LTFU. However, scores on some cognitive items were worse in LTFU BC patients than in non-BC controls raising concerns that BC diagnosis and treatment may be associated with long-term adverse effects on some aspects of self-reported cognitive attributes.
(Funded by The Breast Cancer Research Foundation)
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD04-09.
Collapse
Affiliation(s)
- T Hsu
- 1University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Mount Sinai and Princess Margaret Hospitals, Samuel Lunenfeld Research Institue, University of Toronto, Toronto, ON, Canada
| | - M Ennis
- 1University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Mount Sinai and Princess Margaret Hospitals, Samuel Lunenfeld Research Institue, University of Toronto, Toronto, ON, Canada
| | - N Hood
- 1University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Mount Sinai and Princess Margaret Hospitals, Samuel Lunenfeld Research Institue, University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- 1University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Mount Sinai and Princess Margaret Hospitals, Samuel Lunenfeld Research Institue, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
34
|
Rowan S, Bradley J, Ennis M, Horsley A, Bell N, Gustafsson P, Elborn JS. P133 Lung clearance index is a reproducible and sensitive measure of airways disease in bronchiectasis. Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054c.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Furnari F, Fenton T, Nathanson D, de Alberquerque CP, Kuga D, Wanami A, Dang J, Yang H, Tanaka K, Gao L, Oba-Shinjo S, Uno M, Inda MDM, Bachoo R, James CD, DePinho R, Vandenberg S, Zhou H, Marie S, Mischel P, Cavenee W, Szerlip N, Pedraza A, Huse J, Mikkelsen T, Brennan C, Szerlip N, Castellani RJ, Ivanova S, Gerzanich VV, Simard JM, Ito M, See W, Mukherjee J, Ohba S, Tan IL, Pieper RO, Lukiw WJ, Culicchia F, Pogue A, Bhattacharjee S, Zhao Y, Proescholdt MA, Merrill M, Storr EM, Lohmeier A, Brawanski A, Abraham S, Jensen R, Khatua S, Gopal U, Du J, He F, Golub T, Isaacs JS, Dietrich J, Kalogirou-Valtis Y, Ly I, Scadden D, Proschel C, Mayer-Proschel M, Rempel SA, Schultz CR, Golembieski W, Brodie C, Mathew LK, Skuli N, Mucaj V, Imtiyaz HZ, Venneti S, Lal P, Zhang Z, Davuluri RV, Koch C, Evans S, Simon MC, Ranganathan P, Clark P, Salamat S, Kuo JS, Kalejta RF, Bhattacharjee B, Renzette N, Moser RP, Kowalik TF, McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN, Lawrence JE, Cook NJ, Rovin RA, Winn RJ, Godlewski JA, Ogawa D, Bronisz A, Lawler S, Chiocca EA, Lee SX, Wong ET, Swanson KD, Liu KW, Feng H, Bachoo R, Kazlauskas A, Smith EM, Symes K, Hamilton RL, Nagane M, Nishikawa R, Hu B, Cheng SY, Silber J, Jacobsen A, Ozawa T, Harinath G, Brennan CW, Holland EC, Sander C, Huse JT, Sengupta R, Dubuc A, Ward S, Yang L, Northcott P, Kroll K, Taylor M, Wechsler-Reya R, Rubin J, Chu WT, Lee HT, Huang FJ, Aldape K, Yao J, Steeg PS, Lu Z, Xie K, Huang S, Sim H, Agudelo-Garcia PA, Hu B, Viapiano MS, Hu B, Agudelo-Garcia PA, Saldivar J, Sim H, Dolan C, Mora M, Nuovo G, Cole S, Viapiano MS, Stegh AH, Ryu MJ, Liu Y, Du J, Zhong X, Marwaha S, Li H, Wang J, Salamat S, Chang Q, Zhang J, Ng HK, Yang L, Poon WS, Zhou L, Pang JC, Chan A, Didier S, Kwiatkowska A, Ennis M, Fortin S, Rushing E, Eschbacher J, Tran N, Symons M, Roldan G, McIntyre JB, Easaw J, Magliocco A, Wykosky J, Cavenee W, Furnari F, Lu D, Mreich E, Chung S, Teo C, Wheeler H, McDonald KL, Lawn S, Forsyth P, Sonabend AM, Lei L, Kennedy B, Soderquist C, Guarnieri P, Leung R, Yun J, Sisti J, Castelli M, Bruce S, Bruce R, Ludwig T, Rosenfeld S, Bruce JN, Canoll P, Lamszus K, Schulte A, Gunther HS, Riethdorf S, Phillips HS, Westphal M, Siegal T, Zrihan D, Granit A, Lavon I, Singh M, Chandra J, Ogawa D, Nakashima H, Godlewski J, Chiocca AE, Kapoor GS, Poptani H, Ittyerah R, O'Rourke DM, Sadraei NH, Burgett M, Ahluwalia M, Tipps R, Khosla D, Weil R, Nowacki A, Prayson R, Shi T, Gladson C, Moeckel S, Meyer K, Bosserhoff A, Spang R, Leukel P, Vollmann A, Jachnick B, Stangl C, Proescholdt M, Bogdahn U, Hau P, Kaur G, Sun M, Kaur R, Bloch O, Jian B, Parsa AT, Hossain A, Shinojima N, Gumin J, Feng G, Lang FF, Li L, Yang CR, Chakraborty S, Hatanpaa K, Chauncey S, Jiwani A, Habib A, Nguyen T, Nakashima H, Chiocca EA, Munson J, Machaidze R, Kaluzova M, Bellamkonda R, Hadjipanayis CG, Zhang Y, McFarland B, Bredel M, Benveniste EN, Lee SH, Zerrouqi A, Khwaja F, Devi NS, Van Meir EG, Haseley A, Boone S, Wojton J, Yu L, Kaur B, Wojton JA, Naduparambil J, Denton N, Chakravarti A, Kaur B, Conrad CA, Wang X, Sheng X, Nilsson C, Marshall AG, Emmett MR, Hu Y, Mark L, Zhou YHZ, Dhruv H, McDonough W, Tran N, Armstrong B, Tuncali S, Eschbacher J, Kislin K, Berens M, Plas D, Gallo C, Stringer K, Kendler A, McPherson C, Castelli MA, Ellis JA, Assanah M, Bruce JN, Canoll P, Ogden A, Liang J, Piao Y, deGroot JF, Gordon N, Patel D, Chakravarti A, Palanichamy K, Hervey-Jumper S, Wang A, He X, Zhu T, Heth J, Muraszko K, Fan X, Nakashima H, Nguyen T, Chiocca EA, Liu WM, Huang P, Rani S, Stettner MR, Jerry S, Dai Q, Kappes J, Tipps R, Gladson CL, Chakravarty D, Pedraza A, Koul D, Alfred Yung WK, Brennan CW, Jensen SA, Luciano J, Calvert A, Nagpal V, Stegh A, Kang SH, Yu MO, Lee MG, Chi SG, Chung YG, Cooper MK, Valadez JG, Grover VK, Kouri FM, Chin L, Stegh AH, Ahluwalia MS, Khosla D, Weil RJ, McGraw M, Huang P, Prayson R, Nowacki A, Barnett GH, Gladson C, Kang C, Zou J, Lan F, Yue X, Shi Z, Zhang K, Han L, Pu P, Seaman BF, Tran ND, McDonough W, Dhruv H, Kislin K, Berens M, Battiste JD, Sirasanagandla S, Maher EA, Bachoo R, Sugiarto S, Persson A, Munoz EG, Waldhuber M, Vandenberg S, Stallcup W, Philips J, Berger MS, Bergers G, Weiss WA, Petritsch C. CELL BIOLOGY AND SIGNALING. Neuro Oncol 2011; 13:iii10-iii25. [PMCID: PMC3199169 DOI: 10.1093/neuonc/nor148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2023] Open
|
36
|
Hanrahan S, Stokesberry S, McGarvey L, Elborn J, Zholos A, Ennis M. Expression and Functional Role of Trpm8 in Primary Human Nasal Epithelial Cells. Pulm Pharmacol Ther 2011. [DOI: 10.1016/j.pupt.2011.04.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Stokesberry S, Hanrahan S, Polley L, Zholos A, Ennis M, McGarvey L. Functional Expression of Trpv1 in Primary Bronchial Epithelial Cells. Pulm Pharmacol Ther 2011. [DOI: 10.1016/j.pupt.2011.04.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Kelly C, Williams M, Elborn J, Ennis M, Schock B. 177* Expression of the NF-κB inhibitor A20 reflects cystic fibrosis disease severity. J Cyst Fibros 2011. [DOI: 10.1016/s1569-1993(11)60193-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Cescon DW, Ennis M, Ganz PA, Beddows S, Stanczyk FZ, Sridhar SS, Goodwin PJ. An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Davey P, Schwartz M, Scora D, Ennis M, Smith J. Fractionated Radiosurgery for Recurrent Brain Metastases: Long Term Outcomes. Clin Oncol (R Coll Radiol) 2011. [DOI: 10.1016/j.clon.2011.01.355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Cescon DW, Ganz PA, Hallak S, Ennis M, Mills BK, Goodwin PJ. Abstract P5-13-09: Feasibility of a Randomized Controlled Trial of Vitamin D vs. Placebo in Recently Diagnosed Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-13-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Vitamin D (Vit D) supplementation is an area of interest in the primary and secondary prevention of many cancers. We previously reported a high prevalence of Vit D insufficiency and deficiency in newly diagnosed breast cancer (BC) patients. Low Vit D levels were associated with poor BC outcomes. Here we evaluate the state of Vit D adequacy and supplementation in a more recently diagnosed cohort of BC patients from 2 large urban centres, and we examine the feasibility of a placebo-controlled randomized trial (RCT) of supplementation in this population. Patients and Methods: Women diagnosed with T1-3, N0-3, M0 invasive BC within the previous 2 years were prospectively identified from institutional registries and recruited from Mount Sinai Hospital, Toronto and UCLA, Los Angeles (LA), between March 2009 and January 2010. Anthropometric measurements were performed, and dietary, lifestyle and medication histories were obtained using structured questionnaires and interviews. Tumor and treatment characteristics were obtained from clinical records; blood samples were collected for analysis of Vit D levels. The pre-specified feasibility criteria for a Vit D (vs placebo) RCT were: ≥30% of patients with (i) deficient or insufficient Vit D levels, (ii) taking ≥1000 IU Vit D/day and (iii) willing to participate in such a trial.
Results: 173 eligible patients were enrolled (80 Toronto, 93 LA). Median age at enrollment was 57 years; 73.4% were post-menopausal. Median tumor size (1.8 cm), lymph node involvement (39%), ER (80%), PR (65%) and Her2 (15%) positivity were similar between centres. Treatment characteristics including rates of mastectomy (44%), adjuvant chemotherapy (56%), radiation (68%), hormonal therapy (69%) and trastuzumab (14%) did not differ between centres. 84.4% of women reported use of Vit D containing supplements, with median daily doses of 1200 IU (Toronto) and 1400 IU (LA) (p=0.3) among users. Respective median 25-OH Vit D levels were 85.5 nmol/L (34.3 ng/mL) and 98.5 nmol/L (39.5 ng/mL) (p=0.04), and rates of deficiency, insufficiency and adequacy were 3.8%, 23.8%, 72.5% (Toronto) and 4.3%, 20.7%, 75.0% (LA) (p=0.88). No Vit D levels were in the toxic range. 25-OH Vit D levels correlated with Vit D supplement use (r=0.41, P<0.0001). 68% of women expressed willingness to participate in a Vit D RCT; however, only 12.7% of the study population met the pre-specified feasibility criteria.
Conclusions: Vit D levels and supplementation rates are substantially higher in these BC patients than in previous cohorts, though more than 25% of women do not have adequate levels. Rates of adequacy did not
differ between patients recruited in Toronto and LA. While the maj ority of women would be willing to participate in an RCT of Vit D supplementation, low levels of deficiency/insufficiency and high rates of supplement use may limit the feasibility of such a study. Funded by the Breast Cancer Research Foundation.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-13-09.
Collapse
Affiliation(s)
- DW Cescon
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - PA Ganz
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - S Hallak
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - M Ennis
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - BK Mills
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - PJ. Goodwin
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| |
Collapse
|
42
|
Comer D, Elborn JS, Brown V, McDowell C, Ennis M. S145 The impact of cigarette smoke extract on inflammatory responses and toll-like receptor-4 expression in healthy nasal epithelial cells. Thorax 2010. [DOI: 10.1136/thx.2010.150946.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Fishman RA, Happ E, Stevens T, Kunschner L, Jaworski DM, Stradecki HM, Penar PL, Pendlebury WW, Pennington CJ, Edwards DR, Broaddus WC, Fillmore HL, Mukherjee J, Hawkins C, Guha A, Pioli PD, Milani S, Linskey ME, Zhou YH, Marchetti V, Barnett F, Wang M, Scheppke L, Sanchez-Cespedes J, De Rossi C, Nemerow G, Torbett B, Friedlander M, Goldlust SA, Singer S, DeAngelis LM, Lassman AB, Nolan CP, Yang SH, Lee SW, Chen ZP, Liu XM, Wojton JA, Chu Z, Qi X, Kaur B, Zhou YH, Hu Y, Pioli PD, Siegel E, Ro DI, Marlon S, Hsu N, Milani SN, Mohan S, Yu L, Hess KR, Linskey ME, Liu Y, Carson-Walter E, Walter K, Raghu H, Gondi CS, Gujrati M, Dinh DH, Rao JS, Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E, Knopp E, Zagzag D, Gruber D, Gruber ML, Burrell K, Jelveh S, Lindsey P, Hill R, Zadeh G, Ivkovic S, Beadle C, Massey SC, Swanson KR, Canoll P, Rosenfeld SS, McAllister S, Soroceanu L, Pakdel A, Limbad C, Adrados I, Desprez PY, Nakada M, Nambu E, Furuyama N, Yoshida Y, Kita D, Hayashi Y, Hayashi Y, Hamada JI, Seyed Sadr M, Maret D, Seyed Sadr E, Siu V, Alshami J, Denault JS, Faury D, Jabado N, Nantel A, Del Maestro R, Kunnakkat SD, Perretta D, Medabalmi P, Gruber ML, Gruber D, Golfinos J, Parker E, Narayana A, Pioli PD, Linskey ME, Zhou YH, Nagaiah G, Almubarak M, Torres-Trejo A, Newton, M, Willey P, Altaha R, Murphy SF, Banasiak M, Yee GT, Wotoczek-Obadia M, Tran Y, Prak A, Albright R, Mullan M, Paris D, Brem S, Yang YP, Ennis M, Tran N, Symons M, Najbauer J, Huszthy PC, Garcia E, Metz MZ, Gutova M, Frank RT, Miletic H, Glackin CA, Barish ME, Bjerkvig R, Aboody KS, Clump DA, Engh JA, Mintz AH, Cunnick J, Flynn DC, Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MYC, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK, Megyesi JF, Costello P, Macdonald W, Dyer E, Macdonald D, Hammond R, Kalache Y, Easaw J, McIntyre J, Williams SC, Karajannis MA, Chiriboga L, von Deimling A, Zagzag D, Ajlan A, Husaine S, Petrecca K, Magnus N, Garnier D, Meehan B, Rak J. Angiogenesis and Invasion. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Taylor SK, Ennis M, Hood NS, Graham M, Pritchard KI, Goodwin PJ. Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Bordeleau L, Jugovic O, Ennis M, Pritchard KI, Warr D, Haq R, Loprinzi CL, Goodwin PJ. A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Nai Q, Dong HW, Linster C, Ennis M. Activation of alpha1 and alpha2 noradrenergic receptors exert opposing effects on excitability of main olfactory bulb granule cells. Neuroscience 2010; 169:882-92. [PMID: 20466037 DOI: 10.1016/j.neuroscience.2010.05.010] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2010] [Revised: 05/01/2010] [Accepted: 05/05/2010] [Indexed: 10/19/2022]
Abstract
The mammalian main olfactory bulb (MOB) receives a dense noradrenergic innervation from the pontine nucleus locus coeruleus that is important for neonatal odor preference learning and odor processing in mature animals. Modulation of GABAergic granule cells (GCs) is thought to play a key role in the net functional impact of norepinephrine (NE) release in the MOB, yet there are few direct studies of the influence of NE on these cells. In the present study we investigated noradrenergic modulation of GC excitability using electrophysiological approaches in rat MOB slices. A moderate concentration of NE (10 microM) and the alpha1 receptor agonist phenylephrine (10 microM) depolarized and increased spontaneous or current injection-evoked spiking in GCs. By contrast, low NE concentrations (0.1-1.0 microM) or the alpha2 receptor agonist clonidine (Clon, 10 microM) hyperpolarized and decreased the discharge of GCs. The effects of NE (10 microM) were blocked by antagonism of alpha1 and alpha2 receptors. Inhibitory effects of low NE concentrations were blocked or converted to excitatory responses by alpha2 receptor blockade, whereas excitatory effects of the moderate NE concentration were converted to inhibitory responses after alpha1 receptor blockade. NE (10 microM) and phenylephrine elicited inward currents that reversed near the potassium equilibrium potential. The effects of NE and phenylephrine were associated with increased membrane input resistance. Clonidine elicited an outward current associated with decreased membrane input resistance that reversed near the potassium equilibrium potential. These results indicate that alpha1 and alpha2 receptor activation exert opposing effects on GC excitability. Low concentrations of NE acting via alpha2 receptors suppress GC excitability, while higher concentrations of NE acting at alpha1 receptors increase GC excitability. These findings are consistent with recent findings that alpha1 and alpha2 receptor activation increase and decrease, respectively, GABAergic inhibition of mitral cells. The differential affinities of alpha1 and alpha2 noradrenergic receptor subtypes may allow for differential modulation of GABA release and olfactory processing as a function of the level of NE release, which in turn, is regulated by behavioral state.
Collapse
Affiliation(s)
- Q Nai
- Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
| | | | | | | |
Collapse
|
47
|
|
48
|
Ennis M, Mannaioni P, Pearce F, Sturman G. Honorary memberships in the European Histamine Research Society. Inflamm Res 2009; 59 Suppl 2:S179-81. [PMID: 20013026 DOI: 10.1007/s00011-009-0139-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Affiliation(s)
- M Ennis
- The Queen's University of Belfast, Belfast, Northern Ireland, UK
| | | | | | | |
Collapse
|
49
|
Abstract
BACKGROUND Data on whether the phenotype of cystic fibrosis (CF) patients with compound heterozygocity for G551D (Gly551Asp) differs from patients with F508del (Phe508del) homozygous mutations is divergent. AIM We hypothesized that CF patients with the G551D mutation would have less severe disease than F508del homozygotes. DESIGN We compared the clinical phenotype of adult patients with a G551D mutation with adult patients homozygous for F508del and those with the missense mutation R117H (Arg117His). Compound heterozygotes for the G551D and R117H were analysed separately. METHODS Data were collected for 101 adult CF patients. Group 1-4 represents in order F508del homozygote patients (n = 61), those with the G551D mutation and a more severe mutation (n = 13), those with R117H mutation and a more severe mutation (n = 23) and also those compound for both the R117H and G551D mutations (n = 4). RESULTS Our findings have shown that adult patients with the G551D mutation and a second severe mutation have a milder clinical phenotype than F508del homozygous adult patients. Higher FEV(1) and body mass index and less impaired glucose tolerance was demonstrated in the patients with G551D and R117H compared to F508del homozygotes. There was a reduced yearly rate of decline of FEV(1) (P < 0.05), infection with Pseudomonas aeruginosa along with reduced burden of care. Compound heterozygosity for G551D and R117H mutations was associated with normal spirometry, body mass index, no chronic infection and no symptoms. CONCLUSION Mutations on different chromosomes are not independent of each other for the overall impact on the amount of functional CFTR. This study suggests that patients with the G551D mutation and a second severe mutation have a milder clinical phenotype than F508del homozygous patients, but the phenotype is not as mild as patients with the R117H mutation.
Collapse
Affiliation(s)
- D M Comer
- Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, N Ireland, Antrim BT9 7AB, UK
| | | | | | | | | | | | | |
Collapse
|
50
|
Goodwin P, Pritchard K, Ennis M, Koo J, Hood N. 5160 Long-term prognostic effects of fasting insulin in early stage breast cancer (BC) patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71052-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|